To evaluate the drug efficacy of lashunadi vati in udavartini yonivyapad with special reference to Primary dysmenorrhoea

Randomized Controlled Clinical Study To Evaluate The Efficacy Of Lashunadi Vati In The Management Of Udavartini Yonivyapad With Special Reference To Primary Dysmenorrhoea - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/01/100954

Enrollment

110

Registered

2026-01-13

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N944- Primary dysmenorrhea

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients on hormonal therapy. 2.Pelvic Inflammatory Disease, uterine fibroid, Adenomyosis. 3.Known case of structural anomalies of genital tract. 4.Known case of immune compressive diseases like HIV, HBsAg.

Exclusion criteria

Exclusion criteria: 1. Patients on hormonal therapy. 2. Pelvic Inflammatory Disease, uterine fibroid, Adenomyosis. 3. Known case of structural anomalies of genital tract. 4. Known case of immune compressive diseases like HIV , HBsAg. 5. Known case of life style disorders like DM, HTN, PCOD, Thyroid abnormalities

Design outcomes

Primary

Measure	Time frame
To study in detail the rate and extent of pain relief after the oral administration of Lashunadi vati 250mg BD for consecutive 3 menstrual cycles.Timepoint: 3 months	—

Secondary

Measure	Time frame
-To assess any adverse reaction or side effect related to the oral administration of Lashunadi vati. -To introduce effective ayurvedic medicine for Udavartini yonivyapad.Timepoint: 3 months	—

Countries

India

Contacts

Public ContactShivani Ravindra Tuptewar

Siddhakala Ayurveda College and Research Center Sangamner

vipulbhujbal1@gmail.com9960840214

Outcome results